+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RANKL/RANK signaling in rheumatoid arthritis

RANKL/RANK signaling in rheumatoid arthritis

Clinical Calcium 21(8): 1175-1180

Rheumatoid arthritis (RA) is a chronic inflammatory disease, which is induced by abundant inflammatory cytokines releasing from synovial fibroblasts and T lymphocytes. These cytokines differentiate monocyte-macrophage lineage cells to mature osteoclasts, which cause bone resorption and then joint destruction. RANKL is involved in the development of osteoclasts, cooperating with another key molecule, M-CSF. Indeed, RANKL is over-expressed in the synovium of RA. We summarize RANKL/RANK signaling in RA, including recent therapeutic topics.

(PDF emailed within 1 workday: $29.90)

Accession: 055333213

Download citation: RISBibTeXText

PMID: 21814022

Related references

(5R)-5-hydroxytriptolide (LLDT-8) prevents collagen-induced arthritis through OPG/RANK/RANKL signaling in a rat model of rheumatoid arthritis. Experimental and Therapeutic Medicine 12(5): 3101-3106, 2016

Triptolide Prevents Bone Destruction in the Collagen-Induced Arthritis Model of Rheumatoid Arthritis by Targeting RANKL/RANK/OPG Signal Pathway. Evidence-Based Complementary and Alternative Medicine 2013: 626038-626038, 2013

Regulation of bone destruction in rheumatoid arthritis through RANKL-RANK pathways. World Journal of Orthopedics 4(1): 1-6, 2013

Relationship Between RANK and RANKL Gene Polymorphisms with Osteoporosis in Rheumatoid Arthritis Patients. Genetic Testing and Molecular Biomarkers 20(5): 249-254, 2016

The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. Arthritis and Rheumatism 52(10): 2960-2967, 2005

Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system. Current Opinion in Pharmacology 40: 110-119, 2018

Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system. Current Opinion in Pharmacology 40: 110-119, 2018

Genetic variations in genes encoding RANK, RANKL, and OPG in rheumatoid arthritis: a case-control study. Journal of Rheumatology 37(5): 900-904, 2010

Associations between HLA-DRB1, RANK, RANKL, OPG, and IL-17 genotypes and disease severity phenotypes in Japanese patients with early rheumatoid arthritis. Clinical Rheumatology 26(12): 2137-2141, 2007

Inhibition of RANKL/RANK signaling as a mechanism of the bone-sparing effects of p38 MAPK inhibitors in rodent arthritis. Journal of Bone & Mineral Research 16(Suppl 1): S385, September, 2001

Association between RANK, RANKL and OPG polymorphisms with ACPA and erosions in rheumatoid arthritis: results from a meta-analysis involving three French cohorts. Rmd Open 2(2): E000226-E000226, 2016

Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunological Reviews 208: 30-49, 2005

Discovery of osteoclast differentiation factor, RANKL Inhibition of bone resorption by blocking RANKL-RANK signaling. Japanese Journal of Pharmacology 88(Supplement 1): 17P, 2002

Differential expression of receptor activator of nuclear factor kappa B (RANK) and its ligand (RANKL) in rheumatoid arthritis synovial tissue and peripheral blood cells. 2006

CXCL16 upregulates RANKL expression in rheumatoid arthritis synovial fibroblasts through the JAK2/STAT3 and p38/MAPK signaling pathway. Inflammation Research 65(3): 193-202, 2016